{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:06:36Z","timestamp":1779487596861,"version":"3.53.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11984-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:35:37Z","timestamp":1779442537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ADAM9: an updated view of its biology and pathology"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0858-4878","authenticated-orcid":false,"given":"Akhila","family":"Sheela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6017-4415","authenticated-orcid":false,"given":"Althaf","family":"Mahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6643-2353","authenticated-orcid":false,"given":"Suhail","family":"Subair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4711-3073","authenticated-orcid":false,"given":"Manasa","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-5952","authenticated-orcid":false,"given":"Rajesh","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-121X","authenticated-orcid":false,"given":"Rajesh","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1452-2627","authenticated-orcid":false,"given":"Sowmya","family":"Soman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"20","key":"11984_CR1","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1242\/dev.076398","volume":"139","author":"S Weber","year":"2012","unstructured":"Weber S, Saftig P (2012) Ectodomain shedding and ADAMs in development. Development 139(20):3693\u20133709. https:\/\/doi.org\/10.1242\/dev.076398","journal-title":"Development"},{"issue":"1","key":"11984_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/19336918.2020.1817251","volume":"14","author":"MA Haoyuan","year":"2020","unstructured":"Haoyuan MA, Yanshu LI (2020) Structure, regulatory factors and cancer-related physiological effects of ADAM9. Cell Adh Migr 14(1):165\u2013181. https:\/\/doi.org\/10.1080\/19336918.2020.1817251","journal-title":"Cell Adh Migr"},{"key":"11984_CR3","doi-asserted-by":"publisher","unstructured":"Chou CW, Huang YK, Kuo TT, Liu JP, Sher YP (2020) An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases. Int J Mol Sci 21(20). https:\/\/doi.org\/10.3390\/ijms21207790","DOI":"10.3390\/ijms21207790"},{"issue":"6","key":"11984_CR4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s10930-025-10293-6","volume":"44","author":"A Sujina","year":"2025","unstructured":"Sujina A, Fahma A, Subair S, D\u2019Cunha L, Gopalakrishnan AP, Ummar S, Shivamurthy PB, Ramesh P, Raju R (2025) Unravelling the phosphorylation landscape of anthrax toxin receptor 1: mechanisms and functional insights through phosphoproteomic data integration. Protein J 44(6):742\u2013753. https:\/\/doi.org\/10.1007\/s10930-025-10293-6","journal-title":"Protein J"},{"issue":"20","key":"11984_CR5","doi-asserted-by":"publisher","first-page":"8187","DOI":"10.1158\/0008-5472.CAN-09-4231","volume":"70","author":"JL Fry","year":"2010","unstructured":"Fry JL, Toker A (2010) Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res 70(20):8187\u20138198. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4231","journal-title":"Cancer Res"},{"issue":"11","key":"11984_CR6","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1158\/0008-5472.CAN-04-4449","volume":"65","author":"A De Mazzocca","year":"2005","unstructured":"Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, Toker A (2005) A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 65(11):4728\u20134738. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4449","journal-title":"Cancer Res"},{"issue":"19","key":"11984_CR7","doi-asserted-by":"publisher","first-page":"12135","DOI":"10.1074\/jbc.M114.624072","volume":"290","author":"E Wong","year":"2015","unstructured":"Wong E, Maretzky T, Peleg Y, Blobel CP, Sagi I (2015) The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site. J Biol Chem 290(19):12135\u201312146. https:\/\/doi.org\/10.1074\/jbc.M114.624072","journal-title":"J Biol Chem"},{"issue":"9","key":"11984_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1042\/BCJ20170075","volume":"474","author":"T Maretzky","year":"2017","unstructured":"Maretzky T, Swendeman S, Mogollon E, Weskamp G, Sahin U, Reiss K, Blobel CP (2017) Characterization of the catalytic properties of the membrane-anchored metalloproteinase ADAM9 in cell-based assays. Biochem J 474(9):1467\u20131479. https:\/\/doi.org\/10.1042\/BCJ20170075","journal-title":"Biochem J"},{"issue":"2","key":"11984_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/BJ20041133","volume":"385","author":"RM Mahimkar","year":"2005","unstructured":"Mahimkar RM, Visaya O, Pollock AS, Lovett DH (2005) The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J 385(2):461\u2013468. https:\/\/doi.org\/10.1042\/BJ20041133","journal-title":"Biochem J"},{"issue":"11","key":"11984_CR10","doi-asserted-by":"publisher","first-page":"11925","DOI":"10.1096\/fj.201801371R","volume":"33","author":"R Wichert","year":"2019","unstructured":"Wichert R, Scharfenberg F, Colmorgen C, Koudelka T, Schwarz J, Wetzel S, Potempa B, Potempa J, Bartsch JW, Sagi I, Tholey A, Saftig P, Rose-John S, Becker-Pauly C (2019) Meprin beta induces activities of A disintegrin and metalloproteinases 9, 10, and 17 by specific prodomain cleavage. FASEB J 33(11):11925\u201311940. https:\/\/doi.org\/10.1096\/fj.201801371R","journal-title":"FASEB J"},{"issue":"24","key":"11984_CR11","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1093\/emboj\/17.24.7260","volume":"17","author":"Y Izumi","year":"1998","unstructured":"Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E (1998) A metalloprotease-disintegrin, MDC9\/meltrin-gamma\/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17(24):7260\u20137272. https:\/\/doi.org\/10.1093\/emboj\/17.24.7260","journal-title":"EMBO J"},{"issue":"51","key":"11984_CR12","doi-asserted-by":"publisher","first-page":"15394","DOI":"10.1021\/bi026458q","volume":"41","author":"S Mohan","year":"2002","unstructured":"Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H, Baylink DJ (2002) ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry 41(51):15394\u201315403. https:\/\/doi.org\/10.1021\/bi026458q","journal-title":"Biochemistry"},{"issue":"12","key":"11984_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.43313","volume":"77","author":"K Karino","year":"2025","unstructured":"Karino K, Umeda M, Vichos T, Pan W, Kono M, Tsokos MG, Tsokos GC (2025) ADAM9 promotes glycolysis in Th17 cells and autoimmunity through activation of IGF-1 signaling. Arthritis Rheumatol 77(12):1689\u20131696. https:\/\/doi.org\/10.1002\/art.43313","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"11984_CR14","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1128\/MCB.01460-08","volume":"29","author":"V Guaiquil","year":"2009","unstructured":"Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP (2009) ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 29(10):2694\u20132703. https:\/\/doi.org\/10.1128\/MCB.01460-08","journal-title":"Mol Cell Biol"},{"issue":"20","key":"11984_CR15","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.2174\/138161209788682415","volume":"15","author":"L Peduto","year":"2009","unstructured":"Peduto L (2009) ADAM9 as a potential target molecule in cancer. Curr Pharm Des 15(20):2282\u20132287. https:\/\/doi.org\/10.2174\/138161209788682415","journal-title":"Curr Pharm Des"},{"issue":"4","key":"11984_CR16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/hep.23456","volume":"51","author":"K Kohga","year":"2010","unstructured":"Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N (2010) Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 51(4):1264\u20131273. https:\/\/doi.org\/10.1002\/hep.23456","journal-title":"Hepatology"},{"issue":"4","key":"11984_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/138620710791054259","volume":"13","author":"ML Moss","year":"2010","unstructured":"Moss ML, Rasmussen FH, Nudelman R, Dempsey PJ, Williams J (2010) Fluorescent substrates useful as high-throughput screening tools for ADAM9. Comb Chem High Throughput Screen 13(4):358\u2013365. https:\/\/doi.org\/10.2174\/138620710791054259","journal-title":"Comb Chem High Throughput Screen"},{"key":"11984_CR18","doi-asserted-by":"publisher","unstructured":"Sammel M, Peters F, Lokau J, Scharfenberg F, Werny L, Linder S, Garbers C, Rose-John S, Becker-Pauly C (2019) Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin alpha, Meprin beta and MT1-MMP. Int J Mol Sci 20(15). https:\/\/doi.org\/10.3390\/ijms20153677","DOI":"10.3390\/ijms20153677"},{"issue":"49","key":"11984_CR19","doi-asserted-by":"publisher","first-page":"40624","DOI":"10.1074\/jbc.M506069200","volume":"280","author":"MA Cisse","year":"2005","unstructured":"Cisse MA, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F (2005) The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem 280(49):40624\u201340631. https:\/\/doi.org\/10.1074\/jbc.M506069200","journal-title":"J Biol Chem"},{"issue":"1","key":"11984_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1074\/jbc.M605451200","volume":"282","author":"E Dyczynska","year":"2007","unstructured":"Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A (2007) Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 282(1):436\u2013444. https:\/\/doi.org\/10.1074\/jbc.M605451200","journal-title":"J Biol Chem"},{"issue":"1","key":"11984_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbrc.2012.03.113","volume":"421","author":"WR English","year":"2012","unstructured":"English WR, Corvol P, Murphy G (2012) LPS activates ADAM9 dependent shedding of ACE from endothelial cells. Biochem Biophys Res Commun 421(1):70\u201375. https:\/\/doi.org\/10.1016\/j.bbrc.2012.03.113","journal-title":"Biochem Biophys Res Commun"},{"key":"11984_CR22","doi-asserted-by":"publisher","unstructured":"Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, Ishiura S (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 2003;301(1):231-5. https:\/\/doi.org\/10.1016\/s0006-291x(02)02999-6","DOI":"10.1016\/s0006-291x(02)02999-6"},{"issue":"8","key":"11984_CR23","doi-asserted-by":"publisher","first-page":"102225","DOI":"10.1016\/j.jbc.2022.102225","volume":"298","author":"P Chandrasekera","year":"2022","unstructured":"Chandrasekera P, Perfetto M, Lu C, Zhuo M, Bahudhanapati H, Li J, Chen WC, Kulkarni P, Christian L, Liu J, Yien YY, Yu C, Wei S (2022) Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells. J Biol Chem 298(8):102225. https:\/\/doi.org\/10.1016\/j.jbc.2022.102225","journal-title":"J Biol Chem"},{"issue":"5","key":"11984_CR24","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.4049\/jimmunol.1303370","volume":"193","author":"R Roychaudhuri","year":"2014","unstructured":"Roychaudhuri R, Hergrueter AH, Polverino F, Laucho-Contreras ME, Gupta K, Borregaard N, Owen CA (2014) ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. J Immunol 193(5):2469\u20132482. https:\/\/doi.org\/10.4049\/jimmunol.1303370","journal-title":"J Immunol"},{"key":"11984_CR25","doi-asserted-by":"publisher","unstructured":"Tang SY, Liu DX, Li Y, Wang KJ, Wang XF, Su ZK, Fang WG, Qin XX, Wei JY, Zhao WD, Chen YH (2020) Caspr1 Facilitates sAPPalpha Production by Regulating alpha-Secretase ADAM9 in Brain Endothelial Cells. Front Mol Neurosci 13(23). https:\/\/doi.org\/10.3389\/fnmol.2020.00023","DOI":"10.3389\/fnmol.2020.00023"},{"issue":"3","key":"11984_CR26","doi-asserted-by":"publisher","first-page":"e28497","DOI":"10.4161\/onci.28497","volume":"2014","author":"A Baragano Raneros","year":"2014","unstructured":"Baragano Raneros A, Suarez-Alvarez B, Lopez-Larrea C (2014) Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology 2014(3):e28497. https:\/\/doi.org\/10.4161\/onci.28497","journal-title":"Oncoimmunology"},{"key":"11984_CR27","doi-asserted-by":"publisher","unstructured":"Umeda M, Yoshida N, Hisada R, Burbano C, Orite SYK, Kono M, Kyttaris VC, Krishfield S, Owen CA, Tsokos GC (2021) ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-beta1. Proc Natl Acad Sci U S A 118(18). https:\/\/doi.org\/10.1073\/pnas.2023230118","DOI":"10.1073\/pnas.2023230118"},{"issue":"18","key":"11984_CR28","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1158\/0008-5472.CAN-20-2503","volume":"80","author":"P Yuan","year":"2020","unstructured":"Yuan P, He XH, Rong YF, Cao J, Li Y, Hu YP, Liu Y, Li D, Lou W, Liu MF (2020) Correction: KRAS\/NF-kappaB\/YY1\/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. Cancer Res 80(18):4022. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2503","journal-title":"Cancer Res"},{"issue":"1","key":"11984_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-11-0272","volume":"10","author":"S Hamada","year":"2012","unstructured":"Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, Masamune A, Kikuta K, Kume K, Shimosegawa T (2012) MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 10(1):3\u201310. https:\/\/doi.org\/10.1158\/1541-7786.MCR-11-0272","journal-title":"Mol Cancer Res"},{"issue":"4","key":"11984_CR30","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3892\/or.2017.5460","volume":"37","author":"J Wang","year":"2017","unstructured":"Wang J, Zhou Y, Fei X, Chen X, Yan J, Liu B, Zhu Z (2017) ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol Rep 37(4):2033\u20132040. https:\/\/doi.org\/10.3892\/or.2017.5460","journal-title":"Oncol Rep"},{"issue":"6","key":"11984_CR31","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3892\/ol.2017.7021","volume":"14","author":"C Qin","year":"2017","unstructured":"Qin C, Zhao Y, Gong C, Yang Z (2017) MicroRNA-154\/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells. Oncol Lett 14(6):6969\u20136975. https:\/\/doi.org\/10.3892\/ol.2017.7021","journal-title":"Oncol Lett"},{"issue":"12","key":"11984_CR32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s13238-015-0223-8","volume":"6","author":"C Zhang","year":"2015","unstructured":"Zhang C, Zhang Y, Ding W, Lin Y, Huang Z, Luo Q (2015) MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1. Protein Cell 6(12):881\u2013889. https:\/\/doi.org\/10.1007\/s13238-015-0223-8","journal-title":"Protein Cell"},{"key":"11984_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep16426","author":"KL Chiu","year":"2015","unstructured":"Chiu KL, Kuo TT, Kuok QY, Lin YS, Hua CH, Lin CY, Su PY, Lai LC, Sher YP (2015) ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis. Sci Rep. https:\/\/doi.org\/10.1038\/srep16426","journal-title":"Sci Rep"},{"issue":"1","key":"11984_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13062-024-00572-0","volume":"19","author":"L Li","year":"2024","unstructured":"Li L, He H, Zheng Z, Zhao X (2024) MLL1 promotes placental trophoblast ferroptosis and aggravates preeclampsia symptoms through epigenetic regulation of RBM15\/TRIM72\/ADAM9 axis. Biol Direct 19(1):133. https:\/\/doi.org\/10.1186\/s13062-024-00572-0","journal-title":"Biol Direct"},{"key":"11984_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.placenta.2023.12.008","volume":"146","author":"J Liu","year":"2024","unstructured":"Liu J, Wang Y, Zhang S, Sun L, Shi Y (2024) ADAM9 deubiquitination induced by USP22 suppresses proliferation, migration, invasion, and epithelial-mesenchymal transition of trophoblast cells in preeclampsia. Placenta 146:50\u201357. https:\/\/doi.org\/10.1016\/j.placenta.2023.12.008","journal-title":"Placenta"},{"issue":"7","key":"11984_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41419-020-02786-2","volume":"11","author":"YW Lin","year":"2020","unstructured":"Lin YW, Wen YC, Chu CY, Tung MC, Yang YC, Hua KT, Pan KF, Hsiao M, Lee WJ, Chien MH (2020) Stabilization of ADAM9 by N-alpha-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer. Cell Death Dis 11(7):591. https:\/\/doi.org\/10.1038\/s41419-020-02786-2","journal-title":"Cell Death Dis"},{"issue":"6","key":"11984_CR37","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1074\/jbc.274.6.3531","volume":"274","author":"M Roghani","year":"1999","unstructured":"Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, Blackburn RK, Weskamp G, Tempst P, Blobel CP (1999) Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274(6):3531\u20133540. https:\/\/doi.org\/10.1074\/jbc.274.6.3531","journal-title":"J Biol Chem"},{"issue":"1","key":"11984_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1101\/gad.1039703","volume":"17","author":"DF Seals","year":"2003","unstructured":"Seals DF, Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17(1):7\u201330. https:\/\/doi.org\/10.1101\/gad.1039703","journal-title":"Genes Dev"},{"issue":"11","key":"11984_CR39","first-page":"3828","volume":"10","author":"YS Lin","year":"2020","unstructured":"Lin YS, Hsieh CY, Kuo TT, Lin CC, Lin CY, Sher YP (2020) Resveratrol-mediated ADAM9 degradation decreases cancer progression and provides synergistic effects in combination with chemotherapy. Am J Cancer Res 10(11):3828\u20133837","journal-title":"Am J Cancer Res"},{"issue":"5","key":"11984_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ajhg.2009.04.005","volume":"84","author":"DA Parry Jr.","year":"2009","unstructured":"Parry DA, Toomes C, Bida L, Danciger M, Towns KV, McKibbin M, Jacobson SG, Logan CV, Ali M, Bond J, Chance R, Swendeman S, Daniele LL, Springell K, Adams M, Johnson CA, Booth AP, Jafri H, Rashid Y, Banin E, Strom TM, Farber DB, Sharon D, Blobel CP, Pugh EN Jr., Pierce EA, Inglehearn CF (2009) Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice. Am J Hum Genet 84(5):683\u2013691. https:\/\/doi.org\/10.1016\/j.ajhg.2009.04.005","journal-title":"Am J Hum Genet"},{"issue":"12","key":"11984_CR41","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1136\/bjophthalmol-2014-305231","volume":"98","author":"WM El-Haig","year":"2014","unstructured":"El-Haig WM, Jakobsson C, Favez T, Schorderet DF, Abouzeid H (2014) Novel ADAM9 homozygous mutation in a consanguineous Egyptian family with severe cone-rod dystrophy and cataract. Br J Ophthalmol 98(12):1718\u20131723. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305231","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"11984_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neurobiolaging.2009.01.001","volume":"32","author":"L Cong","year":"2011","unstructured":"Cong L, Jia J (2011) Promoter polymorphisms which regulate ADAM9 transcription are protective against sporadic Alzheimer\u2019s disease. Neurobiol Aging 32(1):54\u201362. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.01.001","journal-title":"Neurobiol Aging"},{"key":"11984_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/jdr\/5519447","author":"H Drobiova","year":"2025","unstructured":"Drobiova H, Al-Mulla F, Al-Temaimi R (2025) ADAM9 Genetic Variants and Their Role in Modulating Enzyme Activity in Diabetes and Metabolic Traits. J Diabetes Res. https:\/\/doi.org\/10.1155\/jdr\/5519447. 2025;2025(5519447","journal-title":"J Diabetes Res"},{"key":"11984_CR44","doi-asserted-by":"publisher","unstructured":"Chang JH, Lai TC, Ho KH, Tsao TC, Chang LC, Yang SF, Chien MH (2025) Potential influence of ADAM9 genetic variants and expression levels on the EGFR mutation status and disease progression in patients with lung Adenocarcinoma. Int J Mol Sci 26(10). https:\/\/doi.org\/10.3390\/ijms26104606","DOI":"10.3390\/ijms26104606"},{"issue":"D1","key":"11984_CR45","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkx973","volume":"46","author":"M Krassowski","year":"2018","unstructured":"Krassowski M, Paczkowska M, Cullion K, Huang T, Dzneladze I, Ouellette BFF, Yamada JT, Fradet-Turcotte A, Reimand J (2018) ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res 46(D1):D901\u2013D10. https:\/\/doi.org\/10.1093\/nar\/gkx973","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"11984_CR46","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41467-024-48524-6","volume":"15","author":"LE Bazzone","year":"2024","unstructured":"Bazzone LE, Zhu J, King M, Liu G, Guo Z, MacKay CR, Kyawe PP, Qaisar N, Rojas-Quintero J, Owen CA, Brass AL, McDougall W, Baer CE, Cashman T, Trivedi CM, Gack MU, Finberg RW, Kurt-Jones EA (2024) ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection. Nat Commun 15(1):4153. https:\/\/doi.org\/10.1038\/s41467-024-48524-6","journal-title":"Nat Commun"},{"issue":"4","key":"11984_CR47","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.62347\/LODV2387","volume":"14","author":"JP Liu","year":"2024","unstructured":"Liu JP, Shen KY, Cheng WC, Chang WC, Hsieh CY, Lo CC, Kuo TT, Lin CC, Liu SJ, Huang WC, Sher YP (2024) ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression. Am J Cancer Res 14(4):1850\u20131865. https:\/\/doi.org\/10.62347\/LODV2387","journal-title":"Am J Cancer Res"},{"issue":"3","key":"11984_CR48","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.21873\/anticanres.16249","volume":"43","author":"K Ogawa","year":"2023","unstructured":"Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, Qiang NA, Ao J, Yumita S, Ishino T, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, Matsumoto S, Arai T, Motohashi S, Kato N (2023) Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors. Anticancer Res 43(3):1043\u20131052. https:\/\/doi.org\/10.21873\/anticanres.16249","journal-title":"Anticancer Res"},{"issue":"1","key":"11984_CR49","doi-asserted-by":"publisher","first-page":"26862","DOI":"10.1038\/s41598-024-76049-x","volume":"14","author":"M AmeliMojarad","year":"2024","unstructured":"AmeliMojarad M, AmeliMojarad M, Wang J, Tavakolpour V, Shariati P (2024) A pan-cancer study of ADAM9\u2019s immunological function and prognostic value particularly in liver cancer. Sci Rep 14(1):26862. https:\/\/doi.org\/10.1038\/s41598-024-76049-x","journal-title":"Sci Rep"},{"issue":"5","key":"11984_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1189\/jlb.3A0914-455R","volume":"97","author":"RS Amendola","year":"2015","unstructured":"Amendola RS, Martin AC, Selistre-de-Araujo HS, Paula-Neto HA, Saldanha-Gama R, Barja-Fidalgo C (2015) ADAM9 disintegrin domain activates human neutrophils through an autocrine circuit involving integrins and CXCR2. J Leukoc Biol 97(5):951\u2013962. https:\/\/doi.org\/10.1189\/jlb.3A0914-455R","journal-title":"J Leukoc Biol"},{"key":"11984_CR51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-2781","author":"Y Huo","year":"2026","unstructured":"Huo Y, Huang Y, Yu X, Han L, Zhang L, Huang L, Yang Y, Zhang N, Yang M (2026) FOSL1 orchestrates epigenetic reprogramming of anaplastic thyroid cancer and suppresses natural killer cell-mediated antitumor immunity. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-2781","journal-title":"Cancer Res"},{"issue":"9","key":"11984_CR52","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-012-1208-6","volume":"61","author":"K Kohga","year":"2012","unstructured":"Kohga K, Tatsumi T, Tsunematsu H, Aono S, Shimizu S, Kodama T, Hikita H, Yamamoto M, Oze T, Aketa H, Hosui A, Miyagi T, Ishida H, Hiramatsu N, Kanto T, Hayashi N, Takehara T (2012) Interleukin-1beta enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunol Immunother 61(9):1425\u20131432. https:\/\/doi.org\/10.1007\/s00262-012-1208-6","journal-title":"Cancer Immunol Immunother"},{"key":"11984_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1777860","author":"F Wu","year":"2026","unstructured":"Wu F, Kim CY, Lee JW, Cho JY (2026) M2-type tumor-associated macrophages promote invasion of canine breast cancer through ADAM9 upregulation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2026.1777860","journal-title":"Front Immunol"},{"key":"11984_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep36207","author":"S Suresh Babu","year":"2016","unstructured":"Suresh Babu S, Thandavarayan RA, Joladarashi D, Jeyabal P, Krishnamurthy S, Bhimaraj A, Youker KA, Krishnamurthy P (2016) MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes. Sci Rep. https:\/\/doi.org\/10.1038\/srep36207","journal-title":"Sci Rep"},{"key":"11984_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27041626","author":"Y Chen","year":"2026","unstructured":"Chen Y, Zhou R, Zhao T, Xiang D, Gong X (2026) The ADAM family of proteases: structure, substrates, and roles in liver diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms27041626","journal-title":"Int J Mol Sci"},{"key":"11984_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2026.110687","author":"T Vichos","year":"2026","unstructured":"Vichos T, Li W, Karino K, Rubin L, Tsokos MG, Pan W, Tsokos GC (2026) ADAM9 supports regulatory T cell stability through TGF-beta-SMAD signaling and is reduced in systemic lupus erythematosus. Clin Immunol. https:\/\/doi.org\/10.1016\/j.clim.2026.110687","journal-title":"Clin Immunol"},{"key":"11984_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-179","author":"FR Fritzsche","year":"2008","unstructured":"Fritzsche FR, Wassermann K, Jung M, Tolle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K, Kristiansen G (2008) ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-8-179","journal-title":"BMC Cancer"},{"issue":"8","key":"11984_CR58","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2005-09-3830","volume":"107","author":"A Karadag","year":"2006","unstructured":"Karadag A, Zhou M, Croucher PI (2006) ADAM-9 (MDC-9\/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. Blood 107(8):3271\u20133278. https:\/\/doi.org\/10.1182\/blood-2005-09-3830","journal-title":"Blood"},{"issue":"6","key":"11984_CR59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ijc.21087","volume":"116","author":"P Zigrino","year":"2005","unstructured":"Zigrino P, Mauch C, Fox JW, Nischt R (2005) Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 116(6):853\u2013859. https:\/\/doi.org\/10.1002\/ijc.21087","journal-title":"Int J Cancer"},{"issue":"35","key":"11984_CR60","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1038\/onc.2017.162","volume":"36","author":"N Giebeler","year":"2017","unstructured":"Giebeler N, Schonefuss A, Landsberg J, Tuting T, Mauch C, Zigrino P (2017) Deletion of ADAM-9 in HGF\/CDK4 mice impairs melanoma development and metastasis. Oncogene 36(35):5058\u20135067. https:\/\/doi.org\/10.1038\/onc.2017.162","journal-title":"Oncogene"},{"issue":"8","key":"11984_CR61","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1074\/jbc.M110.168617","volume":"286","author":"P Zigrino","year":"2011","unstructured":"Zigrino P, Nischt R, Mauch C (2011) The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts. J Biol Chem 286(8):6801\u20136807. https:\/\/doi.org\/10.1074\/jbc.M110.168617","journal-title":"J Biol Chem"},{"issue":"10","key":"11984_CR62","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/jid.2012.153","volume":"132","author":"AN Abety","year":"2012","unstructured":"Abety AN, Fox JW, Schonefuss A, Zamek J, Landsberg J, Krieg T, Blobel C, Mauch C, Zigrino P (2012) Stromal fibroblast-specific expression of ADAM-9 modulates proliferation and apoptosis in melanoma cells in vitro and in vivo. J Invest Dermatol 132(10):2451\u20132458. https:\/\/doi.org\/10.1038\/jid.2012.153","journal-title":"J Invest Dermatol"},{"issue":"4","key":"11984_CR63","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","volume":"24","author":"WG Gunn","year":"2006","unstructured":"Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24(4):986\u2013991. https:\/\/doi.org\/10.1634\/stemcells.2005-0220","journal-title":"Stem Cells"},{"issue":"1","key":"11984_CR64","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41408-024-01133-4","volume":"14","author":"M Evers","year":"2024","unstructured":"Evers M, Stuhmer T, Schreder M, Steinbrunn T, Rudelius M, Jundt F, Ebert R, Hartmann TN, Bargou RC, Rosenwald A, Leich E (2024) Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma. Blood Cancer J 14(1):156. https:\/\/doi.org\/10.1038\/s41408-024-01133-4","journal-title":"Blood Cancer J"},{"key":"11984_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO (2023) Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15071796","journal-title":"Pharmaceutics"},{"key":"11984_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00214","author":"R Zhou","year":"2020","unstructured":"Zhou R, Cho WCS, Ma V, Cheuk W, So YK, Wong SCC, Zhang M, Li C, Sun Y, Zhang H, Chan LWC, Tian M (2020) ADAM9 mediates triple-negative breast cancer progression via AKT\/NF-kappaB pathway. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2020.00214","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"11984_CR67","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41401-018-0199-z","volume":"40","author":"JJ Wang","year":"2019","unstructured":"Wang JJ, Zou JX, Wang H, Duan ZJ, Wang HB, Chen P, Liu PQ, Xu JZ, Chen HW (2019) Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling. Acta Pharmacol Sin 40(8):1067\u20131075. https:\/\/doi.org\/10.1038\/s41401-018-0199-z","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"11984_CR68","first-page":"6547","volume":"8","author":"CZ Wang","year":"2015","unstructured":"Wang CZ, Yuan P, Li Y (2015) MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol 8(6):6547\u20136553","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"11984_CR69","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/modpathol.2010.84","volume":"23","author":"CB de Moelans","year":"2010","unstructured":"Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23(7):1029\u20131039. https:\/\/doi.org\/10.1038\/modpathol.2010.84","journal-title":"Mod Pathol"},{"issue":"7","key":"11984_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/jjco\/hyq030","volume":"40","author":"K Tao","year":"2010","unstructured":"Tao K, Qian N, Tang Y, Ti Z, Song W, Cao D, Dou K (2010) Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: implications for tumor progression and prognosis. Jpn J Clin Oncol 40(7):645\u2013651. https:\/\/doi.org\/10.1093\/jjco\/hyq030","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"11984_CR71","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2005.05.026","volume":"43","author":"M Jinushi","year":"2005","unstructured":"Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N (2005) Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43(6):1013\u20131020. https:\/\/doi.org\/10.1016\/j.jhep.2005.05.026","journal-title":"J Hepatol"},{"key":"11984_CR72","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000373","author":"P Gondaliya","year":"2024","unstructured":"Gondaliya P, Driscoll J, Yan IK, Ali Sayyed A, Patel T (2024) Therapeutic restoration of miR-126-3p as a multi-targeted strategy to modulate the liver tumor microenvironment. Hepatol Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000373","journal-title":"Hepatol Commun"},{"issue":"2","key":"11984_CR73","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/1878-0261.12426","volume":"13","author":"VO Oria","year":"2019","unstructured":"Oria VO, Lopatta P, Schmitz T, Preca BT, Nystrom A, Conrad C, Bartsch JW, Kulemann B, Hoeppner J, Maurer J, Bronsert P, Schilling O (2019) ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol Oncol 13(2):456\u2013479. https:\/\/doi.org\/10.1002\/1878-0261.12426","journal-title":"Mol Oncol"},{"issue":"3","key":"11984_CR74","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-023-00720-x","volume":"5","author":"YK Huang","year":"2024","unstructured":"Huang YK, Cheng WC, Kuo TT, Yang JC, Wu YC, Wu HH, Lo CC, Hsieh CY, Wong SC, Lu CH, Wu WL, Liu SJ, Li YC, Lin CC, Shen CN, Hung MC, Lin JT, Yeh CC, Sher YP (2024) Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. Nat Cancer 5(3):400\u2013419. https:\/\/doi.org\/10.1038\/s43018-023-00720-x","journal-title":"Nat Cancer"},{"key":"11984_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133321","author":"EJ El Slapak","year":"2021","unstructured":"Slapak EJ, Kong L, El Mandili M, Nieuwland R, Kros A, Bijlsma MF, Spek CA (2021) ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13133321","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11984_CR76","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1080\/21691401.2019.1671856","volume":"47","author":"C Xing","year":"2019","unstructured":"Xing C, Ye H, Wang W, Sun M, Zhang J, Zhao Z, Jiang G (2019) Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression. Artif Cells Nanomed Biotechnol 47(1):3920\u20133928. https:\/\/doi.org\/10.1080\/21691401.2019.1671856","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"4","key":"11984_CR77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12032-025-02645-0","volume":"42","author":"XY Zhang","year":"2025","unstructured":"Zhang XY, Zhao CY, Dong JM, Du CP, Zhang CL, Yang AJ, Zhou Q, Liu W, Dang Y, Shang LN, Zhou YN, Wang YP, Wang CY, Wang M, Li M (2025) ADAM9 mediates Cisplatin resistance in gastric cancer cells through DNA damage response pathway. Med Oncol 42(4):122. https:\/\/doi.org\/10.1007\/s12032-025-02645-0","journal-title":"Med Oncol"},{"issue":"10","key":"11984_CR78","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/odi.15383","volume":"31","author":"JW Lu","year":"2025","unstructured":"Lu JW, Shih PC, Chuang SM, Tu WJ, Tsai MH, Tsai YJ, Lin SH (2025) Clinical validation of ADAM9 as a prognostic biomarker in oral cancer. Oral Dis 31(10):2865\u20132877. https:\/\/doi.org\/10.1111\/odi.15383","journal-title":"Oral Dis"},{"issue":"1","key":"11984_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41419-025-07507-1","volume":"16","author":"YF Ding","year":"2025","unstructured":"Ding YF, Ho KH, Lee WJ, Chen LH, Hsieh FK, Tung MC, Lin SH, Hsiao M, Yang SF, Yang YC, Chien MH (2025) Cyclic increase in the histamine receptor H1-ADAM9-Snail\/Slug axis as a potential therapeutic target for EMT-mediated progression of oral squamous cell carcinoma. Cell Death Dis 16(1):191. https:\/\/doi.org\/10.1038\/s41419-025-07507-1","journal-title":"Cell Death Dis"},{"issue":"11","key":"11984_CR80","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1074\/jbc.273.11.6277","volume":"273","author":"S Tomita","year":"1998","unstructured":"Tomita S, Kirino Y, Suzuki T (1998) Cleavage of Alzheimer\u2019s amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism. J Biol Chem 273(11):6277\u20136284. https:\/\/doi.org\/10.1074\/jbc.273.11.6277","journal-title":"J Biol Chem"},{"issue":"47","key":"11984_CR81","doi-asserted-by":"publisher","first-page":"40443","DOI":"10.1074\/jbc.M111.280495","volume":"286","author":"ML De Moss","year":"2011","unstructured":"Moss ML, Powell G, Miller MA, Edwards L, Qi B, Sang QX, De Strooper B, Tesseur I, Lichtenthaler SF, Taverna M, Zhong JL, Dingwall C, Ferdous T, Schlomann U, Zhou P, Griffith LG, Lauffenburger DA, Petrovich R, Bartsch JW (2011) ADAM9 inhibition increases membrane activity of ADAM10 and controls alpha-secretase processing of amyloid precursor protein. J Biol Chem 286(47):40443\u201340451. https:\/\/doi.org\/10.1074\/jbc.M111.280495","journal-title":"J Biol Chem"},{"issue":"16","key":"11984_CR82","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1007\/s00018-019-03173-7","volume":"76","author":"HE Hsia","year":"2019","unstructured":"Hsia HE, Tushaus J, Brummer T, Zheng Y, Scilabra SD, Lichtenthaler SF (2019) Functions of \u2018A disintegrin and metalloproteases (ADAMs)\u2019 in the mammalian nervous system. Cell Mol Life Sci 76(16):3055\u20133081. https:\/\/doi.org\/10.1007\/s00018-019-03173-7","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"11984_CR83","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12974-024-03299-x","volume":"21","author":"J Mao","year":"2024","unstructured":"Mao J, Bao Y, Liu F, Ye Q, Peng J, Nie J, Huang L, Liao Y, Xing Y, Wu D, Wang K, Feng W, Qi S, Pan J, Qiu B (2024) Microglia-derived ADAM9 promote GHRH neurons pyroptosis by Mad2L2-JNK-caspase-1 pathway in subarachnoid hemorrhage. J Neuroinflammation 21(1):302. https:\/\/doi.org\/10.1186\/s12974-024-03299-x","journal-title":"J Neuroinflammation"},{"issue":"7","key":"11984_CR84","doi-asserted-by":"publisher","first-page":"101042831771607","DOI":"10.1177\/1010428317716077","volume":"39","author":"CM Kossmann","year":"2017","unstructured":"Kossmann CM, Annereau M, Thomas-Schoemann A, Nicco-Overney C, Chereau C, Batteux F, Alexandre J, Lemare F (2017) ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype. Tumour Biol 39(7):1010428317716077. https:\/\/doi.org\/10.1177\/1010428317716077","journal-title":"Tumour Biol"},{"issue":"1","key":"11984_CR85","doi-asserted-by":"publisher","first-page":"15108","DOI":"10.1038\/s41598-017-15159-1","volume":"7","author":"CY Lin","year":"2017","unstructured":"Lin CY, Cho CF, Bai ST, Liu JP, Kuo TT, Wang LJ, Lin YS, Lin CC, Lai LC, Lu TP, Hsieh CY, Chu CN, Cheng DC, Sher YP (2017) ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT. Sci Rep 7(1):15108. https:\/\/doi.org\/10.1038\/s41598-017-15159-1","journal-title":"Sci Rep"},{"key":"11984_CR86","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2020.01.014","volume":"297","author":"G Shen","year":"2020","unstructured":"Shen G, Sun Q, Yao Y, Li S, Liu G, Yuan C, Li H, Xu Y, Wang H (2020) Role of ADAM9 and miR-126 in the development of abdominal aortic aneurysm. Atherosclerosis 297:47\u201354. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.01.014","journal-title":"Atherosclerosis"},{"issue":"4","key":"11984_CR87","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/07853890802649738","volume":"41","author":"N Oksala","year":"2009","unstructured":"Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Jarvinen O, Salenius JP, Ozsait B, Komurcu-Bayrak E, Erginel-Unaltuna N, Huovila AP, Kytomaki L, Soini JT, Kahonen M, Karhunen PJ, Laaksonen R, Lehtimaki T (2009) ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries\u2013Tampere vascular study. Ann Med 41(4):279\u2013290. https:\/\/doi.org\/10.1080\/07853890802649738","journal-title":"Ann Med"},{"issue":"4","key":"11984_CR88","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/jcb.10550","volume":"89","author":"N Al-Fakhri","year":"2003","unstructured":"Al-Fakhri N, Wilhelm J, Hahn M, Heidt M, Hehrlein FW, Endisch AM, Hupp T, Cherian SM, Bobryshev YV, Lord RS, Katz N (2003) Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 89(4):808\u2013823. https:\/\/doi.org\/10.1002\/jcb.10550","journal-title":"J Cell Biochem"},{"key":"11984_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178436","author":"MA Gul","year":"2025","unstructured":"Gul MA, Tozcu Yilmaz D, Aydin N, Tufek M, Capraz M (2025) The role of ADAM9 and MMP9 in diabetic retinopathy: insights from ocular parameters. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26178436","journal-title":"Int J Mol Sci"},{"issue":"12","key":"11984_CR90","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1164\/rccm.201805-1012ED","volume":"198","author":"DW Russell","year":"2018","unstructured":"Russell DW, Gaggar A (2018) ADAM9: A damaging player in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 198(12):1465\u20131466. https:\/\/doi.org\/10.1164\/rccm.201805-1012ED","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"11984_CR91","doi-asserted-by":"publisher","first-page":"101042831770912","DOI":"10.1177\/1010428317709128","volume":"39","author":"LY Xiang","year":"2017","unstructured":"Xiang LY, Ou HH, Liu XC, Chen ZJ, Li XH, Huang Y, Yang DH (2017) Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9. Tumour Biol 39(6):1010428317709128. https:\/\/doi.org\/10.1177\/1010428317709128","journal-title":"Tumour Biol"},{"issue":"8","key":"11984_CR92","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/0008-5472.CAN-16-2609","volume":"77","author":"JGM van Kampen","year":"2017","unstructured":"van Kampen JGM, van Hooij O, Jansen CF, Smit FP, van Noort PI, Schultz I, Schaapveld RQJ, Schalken JA, Verhaegh GW (2017) miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2. Cancer Res 77(8):2008\u20132017. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2609","journal-title":"Cancer Res"},{"issue":"4","key":"11984_CR93","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2174\/1871520615666150716105955","volume":"16","author":"D Wan","year":"2016","unstructured":"Wan D, Shen S, Fu S, Preston B, Brandon C, He S, Shen C, Wu J, Wang S, Xie W, Chen B, Liya A, Guo Y, Zheng D, Zhi Q, Peng B (2016) miR-203 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting oncogene ADAM9 and oncogenic long non-coding RNA HULC. Anticancer Agents Med Chem 16(4):414\u2013423. https:\/\/doi.org\/10.2174\/1871520615666150716105955","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"11984_CR94","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/jgh.14029","volume":"33","author":"J Arai","year":"2018","unstructured":"Arai J, Goto K, Stephanou A, Tanoue Y, Ito S, Muroyama R, Matsubara Y, Nakagawa R, Morimoto S, Kaise Y, Lim LA, Yoshida H, Kato N (2018) Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. J Gastroenterol Hepatol 33(5):1075\u20131081. https:\/\/doi.org\/10.1111\/jgh.14029","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"11984_CR95","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00262-020-02660-2","volume":"70","author":"J Arai","year":"2021","unstructured":"Arai J, Goto K, Otoyama Y, Nakajima Y, Sugiura I, Kajiwara A, Tojo M, Ichikawa Y, Uozumi S, Shimozuma Y, Uchikoshi M, Sakaki M, Nozawa H, Nakagawa R, Muroyama R, Kato N, Yoshida H (2021) Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunol Immunother 70(1):203\u2013213. https:\/\/doi.org\/10.1007\/s00262-020-02660-2","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"11984_CR96","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1007\/s13277-014-2975-9","volume":"36","author":"CM Chen","year":"2015","unstructured":"Chen CM, Hsieh YH, Hwang JM, Jan HJ, Hsieh SC, Lin SH, Lai CY (2015) Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1\/2. Tumour Biol 36(5):3407\u20133415. https:\/\/doi.org\/10.1007\/s13277-014-2975-9","journal-title":"Tumour Biol"},{"issue":"1","key":"11984_CR97","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3892\/mmr.2017.7920","volume":"17","author":"D Lei","year":"2018","unstructured":"Lei D, Zhang F, Yao D, Xiong N, Jiang X, Zhao H (2018) Galangin increases ERK1\/2 phosphorylation to decrease ADAM9 expression and prevents invasion in A172 glioma cells. Mol Med Rep 17(1):667\u2013673. https:\/\/doi.org\/10.3892\/mmr.2017.7920","journal-title":"Mol Med Rep"},{"issue":"7","key":"11984_CR98","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1535-7163.MCT-21-0915","volume":"21","author":"JA Scribner","year":"2022","unstructured":"Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, Lucas J, Fuller ME, Son T, Dastur A, Hooley J, Espelin C, Themeles M, Chen FZ, Li Y, Chiechi M, Lee J, Barat B, Widjaja L, Gorlatov S, Tamura J, Ciccarone V, Ab O, McEachem KA, Koenig S, Westin EH, Moore PA, Chittenden T, Gregory RJ, Bonvini E, Loo D (2022) Preclinical Evaluation of IMGC936, a next-generation maytansinoid-based antibody-drug conjugate targeting ADAM9-expressing tumors. Mol Cancer Ther 21(7):1047\u20131059. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0915","journal-title":"Mol Cancer Ther"},{"key":"11984_CR99","doi-asserted-by":"publisher","unstructured":"Lin S, Yao J, Yang J, Shi R, Zhu Z, Qiu Y, Hua H (2025) Abstract A132: DB-1317, a novel ADAM9-targeting antibody-drug conjugate, exhibits potent antitumor activity against multiple gastrointestinal cancers. Molecular Cancer Therapeutics 24(10_Supplement):A132-A. https:\/\/doi.org\/10.1158\/1535-7163.TARG-25","DOI":"10.1158\/1535-7163.TARG-25"},{"key":"11984_CR100","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-25-0461","author":"JA Scribner","year":"2025","unstructured":"Scribner JA, Brown JG, Son T, Jin L, McKenzie C, Nam V, Bush C, Quinonez D, Ford D, Tamura J, Gorlatov S, Summers A, Hav M, Li H, Sharma NK, Zhang X, Diedrich G, Butler S, Bonvini E, Loo D (2025) Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0461","journal-title":"Mol Cancer Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11984-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11984-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:01:59Z","timestamp":1779487319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11984-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11984"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11984-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"807"}}